BIODOL THERAPEUTICS

BIODOL THERAPEUTICS is a French biotechnology company founded in 2015, focused on developing non-opioid treatments for chronic and neuropathic pain.

Headquartered in Montarnaud, France, the company aims to create innovative therapies that target the immune-nervous system interaction involved in pain. BIODOL has raised approximately $5.36 million in funding, primarily from V-Bio Ventures, and is led by CEO Fabien Granier, along with Dr. Marie Gourlay-Chu and Dr. Loïc Laplanche. The company's core technology centers on the FLT3 receptor, which plays a crucial role in chronic neuropathic pain. BIODOL develops FLT3 inhibitors and Negative Allosteric Modulators (NAMs) to block the binding of the cytokine FL to the FLT3 receptor. Their product pipeline includes BDT272, currently in Phase 1 clinical trials, and a series of FLT3 selective antagonists. BIODOL serves the healthcare industry, providing solutions for patients suffering from various pain conditions, while also addressing the opioid crisis by developing safer, non-opioid alternatives.